KIRA8 (AMG-18) is a highly potent, monoselective IRE1α kinase inhibitor with IC50 of 5.9 nM.
KIRA8 demonstrates higher potency than KIRA7 in inhibiting XBP1 splicing in the alveolar epithelial cell line MLE12.
KIRA8 attenuates bleomycin-induced increases in lung weight and hydroxyproline, and decreases mRNA expression of collagen 1A1 and fibronectin in murine model of pulmonary fibrosis.
